Sumitomo Dainippon Pharma Co Ltd - ESG Rating & Company Profile powered by AI
This Sustainability assessment for Sumitomo Dainippon Pharma Co Ltd indicates its transparency towards the UN Sustainable Development Goals. The report of Sumitomo Dainippon Pharma Co Ltd is assembled by All Street Sevva using proprietary Cognitive Robots. This webpage contains a zero-cost E,S&G analysis for Sumitomo Dainippon Pharma Co Ltd.
Sumitomo Dainippon Pharma Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Sumitomo Dainippon Pharma Co Ltd | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Sumitomo Dainippon Pharma Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd offer flexible work?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose water use targets?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Sumitomo Dainippon Pharma Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Sumitomo Dainippon Pharma Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Sumitomo Dainippon Pharma Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose its waste policy?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose energy use targets?
Sign up for free to unlockDoes Sumitomo Dainippon Pharma Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Sumitomo Dainippon Pharma Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Sumitomo Dainippon Pharma Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.